1887

Journal of Medical Microbiology logo

Volume 72, Issue 3

susceptibility profiles of species complex subtypes from deep infections to nine antifungal drugs Open Access

Abstract

The complex can be divided into , , and subtypes. It is uncommon for drug sensitivity tests to type them.

In routine susceptibility reports, drug susceptibility of complex subtypes is lacking.

The aim of this study is to investigate the antifungal susceptibility and clinical distribution characteristics of the complex subtypes causing deep infection in patients.

Non-repetitive strains of complex isolated from deep infection from 2017 to 2019 were collected. Species-level identification was performed using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer and confirmed using gene sequencing, when necessary. Antifungal susceptibility testing was performed using the Sensititre YeastOne system method.

A total of 244 cases were included in the study, including 176 males (72.13 %, 60.69±13.43 years) and 68 females (27.87 %, 60.21±10.59 years). The primary diseases were cancer (43.44 %), cardiovascular disease (25.00 %), digestive system diseases, (18.44 %), infection (6.97 %), and nephropathy (6.15 %). Strains were isolated from the bloodstream (63.11 %), central venous catheters (15.16 %), pus (6.56 %), ascites (5.74 %), sterile body fluid (5.33 %), and bronchoalveolar lavage fluid (BALF, 4.09 %). Of the 244 complex strains, 179 (73.26 %) were identified as , 62 (25.41 %) were , and three (1.23 %) were . Only one strain was resistant to anidulafungin, micafungin, caspofungin, and voriconazole, and it was non-wild-type (NWT) to amphotericin B. Furthermore, six strains were resistant to fluconazole, and one was dose-dependent susceptible. Five strains were NWT to posaconazole. Only one strain was NWT for anidulafungin, micafungin, caspofungin, fluconazole, voriconazole, amphotericin B, and posaconazole, while the rest of the strains were wild-type.

was the main clinical isolate from the complex in our hospital. Most strains were isolated from the bloodstream. The susceptibility rate to commonly used antifungal drugs was more than 96 %. Furthermore, most of the infected patients were elderly male cancer patients.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): azoles , Candida parapsilosiscomplex , drug resistance , echinocandins and wild type
Funding
This study was supported by the:
  • Zhangjiakou Science and Technology Bureau (Award 2121098D)
    • Principle Award Recipient: Minghuahua Zhan
  • Health Commission of Hebei Province (Award 20210702 and 20180843)
    • Principle Award Recipient: Minghuahua Zhan
  • Natural Science Foundation of Hebei Province (Award C2022405023)
    • Principle Award Recipient: WeiZhang
© 2022 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001640
2023-03-15
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/72/3/jmm001640.html?itemId=/content/journal/jmm/10.1099/jmm.0.001640&mimeType=html&fmt=ahah

References

  1. Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk factors for invasive candida infection in critically ill patients: a systematic review and meta-analysis. Chest 2022; 161:345–355 [View Article]
     [Google Scholar]
  2. Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 2019; 25:792–798 [View Article] [PubMed]
     [Google Scholar]
  3. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016. Open Forum Infect Dis 2019; 6:S79–S94 [View Article] [PubMed]
     [Google Scholar]
  4. Zarrinfar H, Kord Z, Fata A. High incidence of azole resistance among Candida albicans and C. glabrata isolates in Northeastern Iran. CMM 2021; 7:18–21 [View Article]
     [Google Scholar]
  5. Arastehfar A, Daneshnia F, Najafzadeh MJ, Hagen F, Mahmoudi S et al. Evaluation of molecular epidemiology, clinical characteristics, antifungal susceptibility profiles, and molecular mechanisms of antifungal resistance of Iranian Candida parapsilosis species complex blood isolates. Front Cell Infect Microbiol 2020; 10:206 [View Article]
     [Google Scholar]
  6. Guo J, Zhang M, Qiao D, Shen H, Wang L et al. Prevalence and antifungal susceptibility of Candida parapsilosis species complex in eastern China: A 15-year retrospective Study by ECIFIG. Front Microbiol 2021; 12:644000 [View Article]
     [Google Scholar]
  7. Arastehfar A, Khodavaisy S, Daneshnia F, Najafzadeh M-J, Mahmoudi S et al. Molecular Identification, Genotypic Diversity, Antifungal Susceptibility, and Clinical Outcomes of Infections Caused by Clinically Underrated Yeasts, Candida orthopsilosis, and Candida metapsilosis: An Iranian Multicenter Study (2014-2019). Front Cell Infect Microbiol 2019; 9:264 [View Article]
     [Google Scholar]
  8. Németh T, D Nosanchuk J, Vagvolgyi C, Gacser A. Enhancing the chemical transformation of Candida parapsilosis. Virulence 2021; 12:937–950 [View Article] [PubMed]
     [Google Scholar]
  9. Sun M, Chen C, Xiao W, Chang Y, Liu C et al. Increase in Candida Parapsilosis Candidemia in Cancer Patients. Mediterr J Hematol Infect Dis 2019; 11:e2019012 [View Article]
     [Google Scholar]
  10. Minooeianhaghighi MH. Recurrent Vulvovaginal Candidiasis: The Causative Agents, Clinical Signs and Susceptibility to Fluconazole in Gonabad City, Northeast Iran. CWHR 2019; 16: [View Article]
     [Google Scholar]
  11. Davari A, Haghani I, Hassanmoghadam F, Nabili M, Shokohi T et al. Echinocandin resistance in Candida parapsilosis sensu stricto: Role of alterations in CHS3, FKS1 and Rho gene expression. J Glob Antimicrob Resist 2020; 22:685–688 [View Article] [PubMed]
     [Google Scholar]
  12. Hassanmoghadam F, Shokohi T, Hedayati MT, Aslani N, Haghani I et al. High prevalence of itraconazole resistance among Candida parapsilosis isolated from Iran. Curr Med Mycol 2019; 5:43–46 [View Article]
     [Google Scholar]
  13. Arikan-Akdagli S, Gülmez D, Doğan Ö, Çerikçioğlu N, Doluca Dereli M et al. First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J Glob Antimicrob Resist 2019; 18:230–234 [View Article] [PubMed]
     [Google Scholar]
  14. Fekkar A, Blaize M, Bouglé A, Normand A-C, Raoelina A et al. Hospital outbreak of fluconazole-resistant Candida parapsilosis: arguments for clonal transmission and long-term persistence. Antimicrob Agents Chemother 2021; 65:e02036-20 [View Article]
     [Google Scholar]
  15. CLSI Performance standards for antifungal susceptibility testing of yeasts. In Clinical and Laboratory Standards Institute CLSI supplement M60; 2020
     [Google Scholar]
  16. CLSI Epidemiological cutoff values for antifungalsusceptibility testing. In Clinical and Laboratory Standards Institute CLSI supplement M59; 2018
     [Google Scholar]
  17. Chakraborty T, Tóth Z, Tóth R, Vágvölgyi C, Gácser A. Iron metabolism, Pseudohypha production, and biofilm formation through a multicopper oxidase in the human-pathogenic fungus Candida parapsilosis. mSphere 2020; 5:e00227-20 [View Article]
     [Google Scholar]
  18. Gómez-Molero E, De-la-Pinta I, Fernández-Pereira J, Groß U, Weig M et al. Candida parapsilosis colony morphotype forecasts biofilm formation of clinical isolates. J Fungi 2021; 7:33 [View Article]
     [Google Scholar]
  19. Anh DN, Hung DN, Tien TV, Dinh VN, Son VT et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam. BMC Infect Dis 2021; 21:523 [View Article] [PubMed]
     [Google Scholar]
  20. Toyoshima H, Unno K, Mizuno M, Tanigawa M, Ishiguro C et al. Candida parapsilosis graft infection presenting as cutaneous leukocytoclastic vasculitis. IDCases 2021; 26:e01336 [View Article]
     [Google Scholar]
  21. Fang H, Huang L, Zhang R, Xie D, Sun H et al. Recurrent arthritis caused by Candida parapsilosis: a case report and literature review. BMC Infect Dis 2019; 19:631 [View Article]
     [Google Scholar]
  22. Haciseyitoğlu D, Çağ Y. An outbreak of candidemia due to Candida parapsilosis in an adult intensive care unit. Infez Med 2019; 27:403–409 [PubMed]
     [Google Scholar]
  23. Shimada K, Tachibana M, Watamura T, Kobayashi H, Matsumoto A et al. Swine abortion caused by Candida parapsilosis. J Vet Med Sci 2021; 83:1666–1669 [View Article] [PubMed]
     [Google Scholar]
  24. Yamin DH, Husin A, Harun A. Risk Factors of Candida parapsilosis Catheter-Related Bloodstream Infection. Front Public Health 2021; 9:631865 [View Article] [PubMed]
     [Google Scholar]
  25. Ponnambath DK, Gopalakrishnan A, Pillai VV, Kaviyil JE, Raja K. Clinical Profile of Prosthetic Valve Endocarditis due to Candida parapsilosis: An 11-year Retrospective Observational Study from a Quaternary Cardiac Referral Institute in India. Indian J Crit Care Med 2021; 25:860–865 [View Article] [PubMed]
     [Google Scholar]
  26. Sakamoto Y, Kawabe K, Suzuki T, Sano K, Ide K et al. Species distribution of Candidemia and their susceptibility in a single Japanese University Hospital: prior micafungin use affects the appearance of Candida parapsilosis and elevation of micafungin MICs in non-parapsilosis Candida species. J Fungi 2021; 7:596 [View Article]
     [Google Scholar]
  27. Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E et al. Method-dependent epidemiological cutoff values for detection of triazole resistance in Candida and Aspergillus species for the sensititre yeastOne colorimetric broth and etest Agar diffusion methods. Antimicrob Agents Chemother 2019; 63:e01651-18 [View Article]
     [Google Scholar]
  28. Pfaller MA, Chaturvedi V, Diekema DJ, Ghannoum MA, Holliday NM et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn Microbiol Infect Dis 2012; 73:365–368 [View Article] [PubMed]
     [Google Scholar]
  29. Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. Epidemiology and molecular basis of resistance to Fluconazole among clinical Candida parapsilosis isolates in Kuwait. Microb Drug Resist 2017; 23:966–972 [View Article]
     [Google Scholar]
  30. Mesini A, Mikulska M, Giacobbe DR, Del Puente F, Gandolfo N et al. Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. Mycoses 2020; 63:361–368 [View Article] [PubMed]
     [Google Scholar]
  31. Demirci-Duarte S, Arikan-Akdagli S, Gülmez D. Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in fluconazole resistance in 21 years. Mycoses 2021; 64:823–830 [View Article] [PubMed]
     [Google Scholar]
  32. Roberto AEM, Xavier DE, Vidal EE, Vidal CF de L, Neves RP et al. Rapid detection of Echinocandins resistance by MALDI-TOF MS in Candida parapsilosis complex. Microorganisms 2020; 8:E109 [View Article]
     [Google Scholar]
  33. Brilhante RSN, Alencar LP de, Bandeira SP, Sales JA, Evangelista AJ de J et al. Exposure of Candida parapsilosis complex to agricultural azoles: An overview of the role of environmental determinants for the development of resistance. Sci Total Environ 2019; 650:1231–1238 [View Article] [PubMed]
     [Google Scholar]
  34. Clinical and Laboratory Standards Institute Performance standards for antifungal susceptibility testing of yeasts; 2017; M60
  35. Clinical and Laboratory Standards Institute Epidemiological cutoff values for antifungal susceptibility testing; 2018; M59
  36. Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J et al. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect 2020; 26:1464–1472 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001640
Loading
In vitro susceptibility profiles of Candida parapsilosis species complex subtypes from deep infections to nine antifungal drugs
J. Med. Microbiol. 72, 001640 (2023); https://doi.org/10.1099/jmm.0.001640
/content/journal/jmm/10.1099/jmm.0.001640
/content/journal/jmm/10.1099/jmm.0.001640
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error